Acute myeloid leukaemia (AML) statistics

Cases

New cases of acute myeloid leukaemia, 2015, UK

Deaths

Deaths from acute myeloid leukaemia, 2016, UK

 

  • There are around 3,100 new acute myeloid leukaemia cases in the UK every year, that's more than 8 every day (2013-2015).
  • Acute myeloid leukaemia is not among the 20 most common cancers in the UK, accounting for less than 1% of all new cancer cases (2015).
  • In males in the UK, acute myeloid leukaemia is not among the 20 most common cancers, with around 1,800 new cases in 2015.
  • In females in the UK, acute myeloid leukaemia is not among the 20 most common cancers, with around 1,400 new cases in 2015.
  • Incidence rates for acute myeloid leukaemia in the UK are highest in people aged 85 to 89 (2013-2015).
  • Since the early 1990s, acute myeloid leukaemia incidence rates have increased by almost a third (30%) in the UK. Rates in males have increased by a third (33%), and rates in females have increased by more than a fifth (22%).
  • Over the last decade, acute myeloid leukaemia incidence rates have increased by almost a tenth (8%) in the UK. Rates in males have increased by a tenth (10%), and rates in females have remained stable.
  • 1 in 200 men and 1 in 255 women will be diagnosed with AML during their lifetime.
  • Leukaemia (AML) in England is more common in males living in the most deprived areas. There is no association for females.
  • An estimated 6,100 people who had previously been diagnosed with acute myeloid leukaemia (AML) were alive in the UK at the end of 2010.

See more in-depth AML incidence statistics

  • There are around 2,500 acute myeloid leukaemia deaths in the UK every year, that's around 7 every day (2014-2016).
  • Acute myeloid leukaemia is not among the 20 most common causes of cancer death in the UK, accounting for 2% of all cancer deaths (2016).
  • In males in the UK, acute myeloid leukaemia is not among the 20 most common causes of cancer death, with around 1,500 deaths in 2016.
  • In females in the UK, acute myeloid leukaemia is not among the 20 most common causes of cancer death, with around 1,100 deaths in 2016.
  • Mortality rates for acute myeloid leukaemia in the UK are highest in people aged 85 to 89 (2014-2016).
  • Since the early 1970s, acute myeloid leukaemia mortality rates have increased by around four-fifths (79%) in the UK. Rates in males have increased by more than nine-tenths (92%), and rates in females have increased by almost three-fifths (58%).
  • Over the last decade, acute myeloid leukaemia mortality rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
  • Leukaemia (AML) deaths in England are not associated with deprivation.

See more in-depth AML mortality statistics

  • Five-year relative survival for acute myeloid leukaemia (AML) in men is similar to the European average in England, Wales and Scotland.
  • Five-year relative survival for acute myeloid leukaemia (AML) in women is below the European average in England but similar to the European average in Scotland.

See more in-depth AML survival statistics

  • ‘Two-week wait’ standards are met by all countries, and ‘31-day wait’ is met by all but England for acute leukaemia.

See more in-depth AML diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

The latest statistics available for acute myeloid leukaemia (AML) in the UK are incidence 2015 and mortality 2016. Reliable survival data for the UK is currently not available.

The ICD codes Open a glossary item for AML are ICD-10 C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0 and C94.2.

European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.

Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.

Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. AML is part of the group 'Acute leukaemia' for cancer waiting times data. Codes vary per country but broadly include: acute lymphoblastic, myeloid and monocytic leukaemia and some other leukaemia of specific or unspecified cell type.

Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.

Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 1.7 out of 5 based on 13 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page